期刊
CELLS
卷 12, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/cells12182237
关键词
CCR5; breast cancer; triple-negative breast cancer
类别
CCR5 functions as a co-receptor for HIV entry into immune cells and recent studies have shown its expression on breast cancer epithelial cells. CCR5 on breast cancer epithelial cells induces aberrant cell survival signaling and tropism towards chemo attractants. Inhibitors of CCR5 have shown promising anti-tumor and anti-metastatic properties in preclinical studies.
The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据